| 货号 | AF767-SP |
| 别名 | vascular endothelial growth factor B; VEGF-B; VEGF-related factor; VRFVEGFL | 全称 | Vascular Endothelial Growth Factor B |
| 反应种属 | Mouse |
| 应用 | Western Blot(0.1 µg/mL) Immunohistochemistry(5-15 µg/mL) |
| 目标/特异性 | Detects mouse VEGF-B186 in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 25% cross‑reactivity with recombinant human (rh) VEGF-B186 is observed and no cross-reactivity with rhVEGF165, recombinant mouse (rm) VEGF-B167, rhVEGF-C, and rmVEGF-D is observed. |
| 使用方法 | Western Blot: 0.1 µg/mL Immunohistochemistry: 5-15 µg/mL |
| 来源 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 7423 (Human); 22339 (Mouse) |
| 应用文献 | |
| R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. Modulation of angiogenesis by a tetrameric tripeptide that antagonizes vascular endothelial growth factor receptor 1. | |
| 纯化方式 | Antigen Affinity-purified |
| 免疫原 | E. coli-derived recombinant mouse VEGF-B186 |
| 内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
| 生物活性 | Mouse |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 背景 | Vascular endothelial growth factor B (VEGF-B; also known as VFR) is a member of the VEGF-PDGF supergene family of growth factor molecules (1‑4). Five mouse members have been identified, including VEGF-A, -B, -C, -D, and PlGF(-2) (1, 5). VEGF family members are disulfide-linked homo- and heterodimeric proteins that are important regulators of vasculogenesis and lymphangiogenesis. Two isoforms of mouse VEGF-B are produced by alternative splicing (6, 7). The long form (VEGF186) is 207 amino acids (aa) in length, with a putative 21 aa signal sequence and a 186 aa (32 kDa) mature region. The short form (VEGF167) is 188 aa in length, with a 21 aa signal sequence and a 167 aa (21 kDa) mature segment. The two isoforms share the same N-terminal 94 aa residue containing the cysteine knot VEGF homology domain (6‑8). VEGF186 is O-glycosylated; VEGF167 is not. VEGF167 binds heparin; VEGF186 does not. Thus, VEGF186 is secreted and freely diffusible in tissues (7). However, the VEGF-B167 isoform is the predominant form in tissue (9). Mouse VEGF-B186 shares 93% and 87% aa identity with bovine and human VEGF‑B186, respectively. Mouse VEGF-B167 also shares 90% and 88% aa identity with bovine and human VEGF-B167, respectively. Unlike VEGF167, VEGF-B186 can undergo proteolytic processing to generate a partially processed 48 kDa heterodimer (16 kDa and 32 kDa) and a fully processed 32 kDa homodimer (two 16 kDa). Processing appears to occur at Arg 127 of the mature protein (10). VEGF-B can heterodimerize with VEGF (7). Both VEGF-B isoforms can bind to VEGF receptor 1 (VEGF R1), but not VEGF R2 or VEGF R3 (11). VEGF-B167 also binds neuropilin-1, but only the 127 aa processed form of VEGF-B186 binds neuropilin-1 (10). As a dimer, the full length VEGF-B186 does not interact with neuropilin-1, while any dimer that contains the processed VEGF-B127 subunit will interact with neuropilin-1 (10). The importance of differential neuropilin binding is unclear. VEGF-B deficient mice display an atrial conduction deficit (12). On endothelial cells, ligation of VEGF R1 by VEGF-B has been shown to regulate the expression and activity of urokinase type plasminogen activator and plasminogen activator inhibitor 1 (11). |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 参考文献 |
|